More than a CRO

Your translational science partner at Pharmidex, we combine deep scientific expertise, translational insight and operational flexibility to go beyond traditional CRO services.

We act as a trusted partner, helping you progress your discoveries with confidence and clarity.

Your Translational Science Partner

At Pharmidex, we go beyond traditional CRO services, combining scientific expertise, flexibility and translational insight to help you advance your discoveries with confidence.

Expert Collaboration

We support toxicology, PK/PD, efficacy, and safety studies across key therapeutic areas. Our scientists work alongside your team to design robust studies, validate models and generate meaningful, decision-driving data.

Flexible & Rigorous Execution

Every study is guided by experienced scientific leadership and built on quality-controlled workflows. We provide real-time updates and adapt study designs as your research evolves ensuring your program stays on track.

Fast & Client-Focused

We prioritize speed without compromising scientific integrity.

Our collaborative approach and responsiveness make us a trusted partner for both new and returning clients.

Seamless Data & Reporting

Access your data securely in real time, with clear, structured reporting at every stage. Post-study consultations help you interpret results and define your next steps.

Advancing Your Research, Together

From early discovery to development, Pharmidex supports your success with precision, transparency and scientific excellence.

2002

Founded in 2002 in London, By Mo Alavijeh and Alan Palmer at the old MRC facilities in Northwick Park.

2004

A partnership with Flexicare.

Supporting the development of applied biomedical technologies and strengthening industry engagement.

2005

Recognition through a UKTI award. Highlighting Pharmidex’s growing role in innovation and international collaboration within the UK life sciences sector.

2007

Collaboration with Genzyme.

Marking early engagement with global pharmaceutical companies and contributing to the company’s expansion into high-value translational research programs

2013

Establishment of a presence within Stevenage Bioscience Catalyst.

Placing Pharmidex at the heart of one of the UK’s leading biotech hubs, fostering collaboration with innovative biotech companies

2013

Bioanalysis Services Expansion
Pharmidex established its Bioanalysis services, delivering robust, GLP-compliant assays to support pharmacokinetics, toxicokinetics and biomarker studies, enhancing its ability to generate high-quality data across drug discovery.

2016

Early involvement with EMEA Knowledge Centre (EKC).

Providing a strong scientific and infrastructure foundation.

2017

Recognition as SME Hertfordshire Business Awards Winner.

Reflecting excellence in business performance and innovation within the regional life sciences sector.

2018

International Expansion

Pharmidex extended its global footprint with the opening of its Bern, Switzerland office in 2018, enabling closer collaboration with European partners and enhancing its ability to support international drug development programs.

2019

Pneumolabs Acquisition
Pharmidex reinforced its respiratory research expertise through the acquisition of Pneumolabs, significantly expanding its capabilities in pulmonary disease models and translational respiratory science.

2020

Medicines and Healthcare products Regulatory Agency recognition.

Reinforcing adherence to high regulatory standards.

2023

Achievement of AAALAC International accreditation.

Demonstrating commitment to the highest standards of animal care, welfare, and scientific integrity.

2024

Histology Services Development
Pharmidex expanded its scientific offering with the development of advanced histology services, providing high-throughput tissue processing, staining and digital pathology solutions, enabling detailed morphological and biomarker analysis.

2025

Clinical Chemistry and Pathology Services

Pharmidex enhanced its integrated service platform through the development of Clinical Chemistry and Pathology capabilities, enabling comprehensive evaluation of safety, toxicity and disease progression, supporting informed decision-making across preclinical studies.

2026

A Trusted Global Partner

From its origins as a specialized preclinical CRO, Pharmidex has grown into a globally trusted partner, supporting drug discovery and development programs across a wide range of therapeutic areas.

Today, the company has contributed to over 17,000 studies, reflecting its extensive experience, scientific depth, and long-standing commitment to delivering high-quality, decision-enabling data.

Pharmidex Integrated Preclinical Platform to Optimize the Efficacy and Safety Leads